The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
Stay Hydrated and Prioritize Protein When digestion is reduced, protein intake can drop, which may slow metabolism
CONTRAVE is a prescription medication designed to aid weight loss in adults with obesity or who are overweight and have weight-related medical problems
Injectable formulations generally demonstrate more predictable pharmacokinetics in post-bypass patients, while oral medications carry higher risk of subtherapeutic dosing or unpredictable absorption due to reduced intestinal surface area and altered transit time
The safety of GLP-1 receptor agonists during breastfeeding has not been well-studied
